On June 1, 2023 Kinnate Biopharma Inc. (Nasdaq: KNTE) ("Kinnate"), a clinical-stage precision oncology company, reported that the company will participate in two upcoming investor conferences (Press release, Kinnate Biopharma, JUN 1, 2023, View Source [SID1234632347]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wednesday, June 7 at 2:30 p.m. ET / 11:30 a.m. PT at the Jefferies Healthcare Conference. Neha Krishnamohan, chief financial officer and executive vice president, corporate strategy, will represent the company in a fireside chat at the conference.

Thursday, June 15 at 12:20 p.m. ET / 9:20 a.m. PT at the Goldman Sachs 44th Annual Global Healthcare Conference. Nima Farzan, chief executive officer, will represent the company in a fireside chat at the conference.
Members of the Kinnate management team will also host investor meetings during the conferences.

Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Kinnate.com. A webcast replay will be made available following the event for 90 days.

On June 1, 2023 Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that the Company’s senior management team will participate at the Jefferies Healthcare Conference in a fireside chat on Thursday, June 8, 2023 at 10:00 a.m. ET in New York, NY (Press release, Karyopharm, JUN 1, 2023, View Source [SID1234632346]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company’s website, View Source, and will be available for replay for 90 days following the event.

On June 1, 2023 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, reported that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 1:30 p.m. EDT in New York (Press release, IGM Biosciences, JUN 1, 2023, View Source [SID1234632344]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentations.

On June 1, 2023 Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, reported that management will be participating in the following investor conferences (Press release, Gritstone Bio, JUN 1, 2023, View Source [SID1234632342]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs 44th Annual Healthcare Conference (Fireside Chat)
Fireside Chat Date and Time: Monday, June 12 at 4:00pm PT
Speaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer
Location: Dana Point, CA
Webcast: View Source

SVB Securities Therapeutics Forum (1x1s)
Conference Dates: July 11-12, 2023
Location: New York, NY

The live webcast will also be available via View Source An archived replay will be accessible for 30 days following the event.

On June 1, 2023 FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, reported that Pete O’Heeron, Founder and Chief Executive Officer, will present a corporate overview next week at the 2023 BIO International Convention in Boston (Press release, FibroBiologics, JUN 1, 2023, https://fibrobiologics.com/fibrobiologics-to-present-corporate-update-at-2023-bio-international-convention/ [SID1234632341]). The presentation is set for 11:30 a.m. EDT on Tuesday, June 6, in Session Room 104A at the Boston Convention & Exhibition Center.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We will highlight our recent progress in developing next-generation fibroblast cell-based therapies in multiple indications," said O’Heeron. "This is an exciting time for the company, and we look forward to connecting in person with members of the life sciences business community at the BIO conference. This is the industry’s largest and most prestigious event and we appreciate BIO’s selection of FibroBiologics as a presenting company that will be featured in the partnering section of the conference."

To schedule a meeting at the BIO International Convention with FibroBiologics, please submit a meeting request through the BIO One-on-One Partnering platform. For more information, please visit FibroBiologics’ website or send an e-mail to FibroBiologics at [email protected].